Vaccine progress

Area of Science:

• Mycology
• Immunology
• Vaccine Development

Background:

• Invasive aspergillosis remains a threat to immunocompromised individuals, with limited treatment efficacy.
• Current anti-mould agents show dismal responses in high-risk populations.
• Vaccination presents a potential alternative strategy for preventing invasive aspergillosis.

Purpose of the Study:

• To investigate the potential of Aspergillus fumigatus components as vaccine candidates.
• To evaluate the protective efficacy of Asp f 3 and its derivatives against invasive pulmonary aspergillosis.
• To identify potential vaccine targets for protecting immunocompromised hosts.

Main Methods:

• Immunization of corticosteroid-immunosuppressed mice with Aspergillus fumigatus hyphal sonicate and recombinant Asp f 3.
• Mass spectrometry to identify serologically recognized proteins.
• Cloning and testing of truncated Asp f 3 variants and T-cell epitopes.
• Evaluation of adjuvant requirements and particulate vaccine formulations.

Main Results:

• Subcutaneous vaccination with hyphal sonicate conferred protection against invasive pulmonary aspergillosis.
• The 19 kDa protein, identified as Asp f 3, was a key target for serological response.
• Recombinant Asp f 3, including truncated non-allergenic forms and T-cell epitopes, demonstrated protective efficacy, with particulate rAsp f 3 being effective without adjuvant.
• Homologues of Asp f 3 exist in other fungal species.

Conclusions:

• Asp f 3 and its modified forms (truncated, T-cell epitopes) are promising vaccine candidates.
• Vaccination strategies targeting Asp f 3 could protect immunocompromised hosts from invasive aspergillosis.
• Further development of Asp f 3-based vaccines may offer a new preventative approach.